A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

This is a first-in-human (FIH), multicenter, open-label Phase I study to investigate the safety, tolerability, preliminary antitumor activity, as well as pharmacokinetics (PK) and pharmacodynamics of XL309 (previously ISM3091) administered alone or in combination with olaparib in participants with advanced solid tumors.

Trial Details

NCT ID
NCT05932862
Phase
PHASE1
Sponsor
Exelixis
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • XL309
  • Olaparib
Locations (sample)
  • Fountain Valley, California, United States|33.70918,-117.95367
  • Jacksonville, Florida, United States|30.33218,-81.65565
  • Orlando, Florida, United States|28.53834,-81.37924
  • Tampa, Florida, United States|27.94752,-82.45843
  • Rochester, Minnesota, United States|44.02163,-92.4699

Key Eligibility Criteria

  • Capable of understanding and complying with protocol requirements.
  • Male or female aged 18 years or older.
  • Eastern Cooperative Oncology Group performance status 0 or 1.
  • Adequate bone marrow and organ function.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →